world-cancer-2017-scientifictracks-abstracts

27 / 28

Page 52
Notes:
conferenceseries.com
Volume 9, Issue 9 (Suppl) J Cancer Sci Ther, an open access journal
ISSN: 1948-5956 World Cancer 2017
October 19-21, 2017
25th WORLD CANCER CONFERENCE
October 19-21, 2017 | Rome, Italy
Kruppel like factor 4 and Heat Shock Protein 27: Potential biomarkers for lung and larynx cancers
Elie Hadchity
Lebanese University, Lebanon
Lung and larynx cancers are among the prevalent human cancers worldwide and no molecular markers are presently used
for predicting prognosis in these cancers. Late detection and lack of standard treatment strategies result in high levels
of mortality and poor prognosis. Prognostic stratification of larynx cancer patients based on molecular prognostic tumor
biomarkers may lead to more efficient clinical management. Krüppel like factor 4 (KLF4) and Heat Shock Protein 27 (HSP27)
are implied in tumorigenesis and are considered promising candidate biomarkers for various cancers. However, their role
in larynx and lung carcinomas remains to be elucidated. Immunohistochemical and reverse transcription-polymerase chain
reaction analyses in larynx and lung cancer tissue samples and normal tissue samples revealed a differential expression of
KLF4 and HSP27 between normal and tumor tissues. KLF4 was significantly decreased in larynx carcinoma compared with
normal tissue, whereas HSP27 was significantly overexpressed in tumor tissues compared with normal tissues, at the protein
and mRNA levels. The KLF4 expression decreased gradually with tumor progression whereas HSP27 expression increased. In
lung cancer, a significant decrease of KLF4 expression was observed in the Non-Small-Cell Lung-Carcinoma (NSCLC) when
compared to normal tissue, while a significant over-expression was detected in the Small-Cell-Lung-Carcinoma (SCLC). KLF4
and HSP27 exhibit opposite functions and roles in the carcinogenic process. Their role in larynx or lung cancer initiation and
progression highlights their use as potential future targets for prognosis and treatment. KLF4 and HSP27 expression levels may
act as potential biomarkers in patients with larynx and lung cancers.
Biography
Elie Hadchity has completed his PhD from Claude Bernard University Lyon, France. He is a Professor at Faculty of Sciences and the Faculty of Medicine of the
Lebanese University. He leads a Research team Antitumor Therapeutic Targeting, and his research work focused on the identification of novel therapeutic targets
and novel biomarkers. He has several papers in reputed journals and an International Patent.
Elie Hadchity, J Cancer Sci Ther 2017, 9:9(Suppl)
DOI: 10.4172/1948-5956-C1-111